Annals of Pharmacotherapy · 2020 · 22 citations · 28 references
MedicineHematologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyHemostasisAnticoagulant ManagementAnticoagulant TherapyAnticoagulation ManagementAnticoagulation TherapyAntithrombotic TherapyThrombosisExtended-duration AnticoagulationLong-term AnticoagulationLong-term Care AnticoagulationLow-molecular-weight Heparin TherapyPrimary Outcome AnalysisTherapeutic Anticoagulation
BACKGROUND: Clinical practice guidelines recommend that cerebral venous thrombosis (CVT) be managed with long-term anticoagulant therapy using warfarin or low-molecular-weight heparin (LMWH) for 3 to 12 months. However, oral factor Xa inhibitors may offer preferable alternative treatment options for these patients. OBJECTIVE: The primary objective was to determine the effectiveness and safety of rivaroxaban or apixaban compared with warfarin or enoxaparin as long-term anticoagulation therapy for patients with a new diagnosis of CVT. METHODS: This was a single-center retrospective review of patients with newly diagnosed CVT who received acute and maintenance anticoagulation treatment. Study groups compared patients who received warfarin, enoxaparin, or an oral factor Xa inhibitor as their maintenance anticoagulant. The primary outcome was recurrent thrombotic events while on anticoagulation. Secondary outcomes included modified Rankin Scale, improved cerebral venous sinus opacification, duration of anticoagulant therapy, bleeding events during anticoagulant therapy, and adverse effects. RESULTS: = 0.7635). There were no significant between-group differences observed regarding any of the secondary outcomes. CONCLUSIONS: Although the sample size is limited, these findings indicate that oral factor Xa inhibitors are a reasonable treatment option for patients with CVT. There was a trend toward more persistent symptoms in patients on warfarin, suggesting a potential improvement in recovery among patients that received an oral factor Xa inhibitor.
28
Paul A. Harris, Robert Taylor, Robert J. Thielke et al. · Journal of Biomedical Informatics · 2008 · 51.7K citations · Full text
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al. · New England Journal of Medicine · 2011 · 9.4K citations · Full text
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger, John H. Alexander, John J.V. McMurray et al. · New England Journal of Medicine · 2011 · 8.9K citations · Full text
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano, Christian T. Ruff, Eugene Braunwald et al. · New England Journal of Medicine · 2013 · 5.1K citations · Full text